- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04675424
Using Artificial Intelligence (AI)-Assisted Pulse Diagnosis Analysis on Precision Critical Medicine.
September 20, 2023 updated by: Chang Gung Memorial Hospital
Precision/personalized medicine becomes an important part of modern medical system in the recent years.
In the past, the treatments for patients have been decided by doctors according patients' symptoms and/or regular biochemical profiles.
However, it is not uncommon that patients' condition varies tremendously even they have same diagnosis, and under such condition, treatment efficacy may be limited due to the heterogeneity among patients.
Therefore, lack of therapeutic efficacy may be not really ineffective, and the main reason may be inadequate patient classification.
For this reason, the "omics"-based personal/precision medicine emerges recently and becomes more and more important.
However, in contrast to feasible and common "personalized" medicine, the approach of precision medicine to the molecular medicine level is still difficult, especially among patients in intensive critical units (ICUs).
In contrast to cancer, which has remarkable advances in the past decades, the precision/personal medicine is more difficult in critical and emergent medicine.
One reason is the amount of omics data is quite huge and thus dealing with omics data is time consuming.
Therefore, it is not effective in daily clinical practice in ICUs care.
For this condition, the investigators propose that the combination of clinical data, including pulse diagnosis by traditional Chinese medicine (TCM) doctor or ANSwatch wrist sphygmomanometer, fluid responsiveness by "Masimo" Radical-7 Pulse CO-Oximeter, and the specific database from monitors in ICUs may be a feasible way to predict outcome among ICU patients.
There are two main goals for this study: (1) After establishing clinical traditional Chinese medicine (TCM) pulse diagnosis and ICU clinical parameters databases, acquiring and features of pulse diagnosis by applying AI and (2) analyzing the correlations between the features of pulse diagnosis and important clinical parameters.
Study Overview
Study Type
Observational
Enrollment (Actual)
45
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ching Wei Yang
- Phone Number: 2611 +88633196200
- Email: ycw0426@gmail.com
Study Locations
-
-
-
Taoyuan, Taiwan, 33378
- Chang Gung Memorial Hospital, Linkou Branch
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
The ICU patient under acute circulatory failure
Description
Inclusion Criteria:
- 1.The patient in ICU is willing to participate in the research project or patient's family member is willing patient to participate in the research project.
- 2.Acute circulatory failure
Exclusion Criteria:
- 1. The patient do not want to participate in the research project or patient's family member do not want the patient to participate in the research project.
- 2. Pregnant woman.
- 3. Goals of treatment is palliative care.
- 4. Patient is heritable immunodeficiency or acquired immunodeficiency.
- 5. Known existing cardiac arrhythmia, valvular heart disease, right ventricular dysfunction, intra-cardiac shunt, air leaking from chest drains, abdominal compartment syndrome.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
28-days mortality
Time Frame: 28 days
|
The investigators track the enrolled ICU patients for 28 days and record the date and cause of participants' death.
|
28 days
|
Pulse diagnosis
Time Frame: Day1, Day4, Day8, Day11, Day15, Day18, Day22, Day25
|
Pulse diagnosis in radial artery is recorded by traditional Chinese medicine physician and ANSwatch wrist sphygmomanometer at the same time.
With the help of artificial intelligence, the investigators will find the correlation/comparison of pulse diagnosis by physician or machine and hope to define which pulse waveform characteristics could predict the prognosis/outcome in ICU patients.
|
Day1, Day4, Day8, Day11, Day15, Day18, Day22, Day25
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hemodynamic status
Time Frame: Day1, Day4, Day8, Day11, Day15, Day18, Day22, Day25
|
Pulse-induced contour cardiac output (PiCCO) is a cardiac output monitor that combines pulse contour analysis and trans-pulmonary thermos-dilution technique.
PiCCO enables assessment of the patient's hemodynamic status to guide fluid or vasoactive drug therapy, especially if complex mixed forms of shock (e.g.
septic and cardio-genic).
Relatively invasive PiCCO measurement requires the insertion of a central venous pressure (CVP) catheter and a thermo-dilution arterial line.
The non-invasive pulse waveform from radial artery in ANSwatch could be one kind of hemodynamic monitor for peripheral circulation.
By artificial intelligence, the investigators could define some correlation or comparison in the pulse waveform between PiCCO and ANSwatch.
|
Day1, Day4, Day8, Day11, Day15, Day18, Day22, Day25
|
Fluid-responsiveness
Time Frame: Day1, Day4, Day8, Day11, Day15, Day18, Day22, Day25
|
Respiratory variations in the pulse oximeter plethysmographic waveform amplitude have been shown to be able predict fluid responsiveness in mechanically ventilated patients.
The investigators use a device [ Masimo corp., Irvine, California, USA] which could automatically and continuously monitor the respiratory variations in the pulse oximeter waveform amplitude (Pleth Variability Index, PVI, unit in %) to predict fluid responsiveness in ICU patients under mechanical ventilation.
This time, the investigators want to find the correlation in the pulse waveform from PVI, PiCCO, or ANSwatch by artificial intelligence analysis.
|
Day1, Day4, Day8, Day11, Day15, Day18, Day22, Day25
|
Heart rate variability
Time Frame: Day1, Day4, Day8, Day11, Day15, Day18, Day22, Day25,
|
Heart Rate Variability (unit in microseconds) represents significant information on autonomic nervous system (ANS)'s regulating function and balance status.
The change (variation) of heart rate during short term (5 minutes) is analyzed with the method of time domain and frequency domain to provide the degree of balance and activity of autonomic nervous system.
Low Frequency (unit in %) is a band of power spectrum range between 0.04 and 0.15 Hz.
Generally, it is a strong indicator of sympathetic activity.
High Frequency (unit in %) is a band of power spectrum range between 0.15 and 0.4 Hz and it reflects parasympathetic (vagal) activity.
LF/HF Ratio indicates overall balance between sympathetic and parasympathetic systems.
There could be some relationship between these parameters and ICU patients' outcome.
|
Day1, Day4, Day8, Day11, Day15, Day18, Day22, Day25,
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 15, 2020
Primary Completion (Actual)
September 6, 2022
Study Completion (Actual)
October 6, 2022
Study Registration Dates
First Submitted
November 1, 2020
First Submitted That Met QC Criteria
December 14, 2020
First Posted (Actual)
December 19, 2020
Study Record Updates
Last Update Posted (Actual)
September 21, 2023
Last Update Submitted That Met QC Criteria
September 20, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NMRPG3K6131
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Shock
-
Assistance Publique - Hôpitaux de ParisTraumabase Group; Capgemini Invent; Ecole polytechnique; EHESS (Ecole des hautes... and other collaboratorsRecruitingWounds and Injuries | Hemorrhagic Shock | Traumatic ShockFrance
-
Biomedizinische Forschungs gmbHMedical University of ViennaCompletedSepsis | Toxic-Shock Syndrome
-
King's College Hospital NHS TrustUniversity Hospital BirminghamCompletedTraumatic Haemorrhagic ShockUnited Kingdom
-
Haukeland University HospitalMinistry of Defence, NorwayCompletedHemorrhagic Shock | Hypovolemic ShockNorway
-
National Institute of Allergy and Infectious Diseases...Completed
-
Massachusetts General HospitalBeth Israel Deaconess Medical Center; Boston Medical Center; Tufts Medical Center and other collaboratorsRecruiting
-
Jason SperryNational Heart, Lung, and Blood Institute (NHLBI)TerminatedHemorrhagic ShockUnited States
-
University of Texas Southwestern Medical CenterUniversity of Washington; Resuscitation Outcomes ConsortiumCompletedHemorrhagic ShockUnited States
-
Ramathibodi HospitalUnknownSeptic Shock | Refractory ShockThailand
-
Assiut UniversityUnknown
Clinical Trials on ANSwatch
-
Taipei Hospital, TaiwanCompleted
-
National Cheng-Kung University HospitalCompletedHeart Rate Variability | Insomnia ChronicTaiwan
-
Taichung Tzu Chi HospitalUnknownBarrett's Esophagus | Non-erosive Reflux DiseaseTaiwan